Liao Yonghe, Lin Yuxuan, Ye Xinqi, Shen Jinhai
School of Pharmaceutical Science, Guangxi Medical University, Nanning, PR China.
Department of Pharmacy, Guangxi Hospital Division of the First Affiliated Hospital Sun Yat-sen University, Nanning, PR China.
JCO Oncol Pract. 2025 Jan 7:OP2400583. doi: 10.1200/OP-24-00583.
The prognostic significance of concomitant statin use in cancer treatment with immune checkpoint inhibitors (ICIs) remains a subject of ongoing investigation. This study aims to clarify the prognostic value of statin use in this patient population and to provide a robust, evidence-based foundation to guide therapeutic decisions.
A systematic search strategy was used across a multitude of digital archives to exhaustively identify all relevant academic literature published up until June 20, 2024. Studies published in English that reported hazard ratios (HRs) for overall survival (OS) and/or progression-free survival (PFS), along with corresponding 95% CIs, were considered eligible for inclusion. Meta-analyses were conducted to calculate combined HRs with 95% CIs.
A total of 25 studies, involving 46,154 patients with cancer, were included in the meta-analysis. The pooled results indicated that concomitant statin use was linked to better OS (HR, 0.80 [95% CI, 0.71 to 0.92]) and PFS (HR, 0.80 [95% CI, 0.69 to 0.92]) in patients with cancer under ICI therapy. Sensitivity analyses further validated the consistency and robustness of the combined results.
On the basis of the available clinical evidence, the concomitant use of statin is linked to an improved prognosis in oncology patients on ICI-based therapy. These observations underscore the potential of statin as an important adjunctive therapy in the treatment paradigm for ICI-treated patients with cancer, thereby establishing their significance as a key consideration in clinical management strategies. Further randomized controlled trials are imperative to validate the effect of statin use within the realm of ICI therapy.
在癌症免疫检查点抑制剂（ICI）治疗中同时使用他汀类药物的预后意义仍是一个正在进行研究的课题。本研究旨在阐明他汀类药物在该患者群体中的预后价值，并提供一个有力的、基于证据的基础来指导治疗决策。
采用系统检索策略，在众多数字档案库中全面识别截至2024年6月20日发表的所有相关学术文献。纳入以英文发表的、报告了总生存期（OS）和/或无进展生存期（PFS）的风险比（HR）以及相应95%置信区间（CI）的研究。进行荟萃分析以计算合并HR及其95%CI。
荟萃分析共纳入25项研究，涉及46154例癌症患者。汇总结果表明，在接受ICI治疗的癌症患者中，同时使用他汀类药物与更好的OS（HR，0.80[95%CI，0.71至0.92]）和PFS（HR，0.80[95%CI，0.69至0.92]）相关。敏感性分析进一步验证了合并结果的一致性和稳健性。
基于现有临床证据，同时使用他汀类药物与接受ICI治疗的肿瘤患者预后改善相关。这些观察结果强调了他汀类药物作为ICI治疗癌症患者治疗模式中重要辅助治疗的潜力，从而确立了其在临床管理策略中作为关键考虑因素的重要性。进一步的随机对照试验对于验证他汀类药物在ICI治疗领域的使用效果至关重要。
